Literature DB >> 12593967

Characterization of the immune response to Leishmania infantum recombinant antigens.

Lucas Pedreira de Carvalho1, Manuel Soto, Selma Jerônimo, Blaise Dondji, Olívia Bacellar, Viviane Luz, Glória Orge Orge, Carlos Alonso, Amélia R Jesus, Edgar M Carvalho.   

Abstract

Leishmaniases have a high prevalence in tropical countries. In order to improve existing diagnostic systems based on total Leishmania proteins, and to identify antigen candidates for vaccine development, an intensive search for the identification of antigens was performed using molecular biology techniques. In this study, the immune response to three L. infantum recombinant antigens was evaluated. Upon stimulation with KMP11, mononuclear cells from leishmaniasis patients produced high levels of IL-10, while a predominant IFN-gamma production could be observed in cultures stimulated with H2A and soluble Leishmania antigen. All the recombinant antigens induced very little IL-5. KMP11 decreased IFN-gamma production by 48% in cultures of peripheral blood mononuclear cells from cutaneous leishmaniasis patients who had been stimulated with soluble Leishmania antigen. Furthermore, antibodies to KMP11 were detected in the sera from all patients with visceral leishmaniasis and in the majority of the sera from patients with cutaneous leishmaniasis or individuals with asymptomatic L. chagasi infection. Thus, KMP11 is recognized by cells and sera of patients with different clinical forms of leishmaniasis, and KMP11, through IL-10 production, proved to be a potent antigen in modulating type 1 immune response.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12593967     DOI: 10.1016/s1286-4579(02)00051-5

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  18 in total

1.  Immunoregulatory profile of monocytes from cutaneous leishmaniasis patients and association with lesion size.

Authors:  É L M Vieira; T S L Keesen; P R Machado; L H Guimarães; E M Carvalho; W O Dutra; K J Gollob
Journal:  Parasite Immunol       Date:  2013-02       Impact factor: 2.280

2.  Humoral and in vivo cellular immunity against the raw insect-derived recombinant Leishmania infantum antigens KMPII, TRYP, LACK, and papLe22 in dogs from an endemic area.

Authors:  Felicitat Todolí; Laia Solano-Gallego; Rafael de Juan; Pere Morell; Maria Del Carmen Núñez; Rodrigo Lasa; Silvia Gómez-Sebastián; José M Escribano; Jordi Alberola; Alhelí Rodríguez-Cortés
Journal:  Am J Trop Med Hyg       Date:  2010-12       Impact factor: 2.345

3.  Leishmania chagasi T-cell antigens identified through a double library screen.

Authors:  Daniella R A Martins; Selma M B Jeronimo; John E Donelson; Mary E Wilson
Journal:  Infect Immun       Date:  2006-09-25       Impact factor: 3.441

4.  Interleukin-4 (IL-4) and IL-10 collude in vaccine failure for novel exacerbatory antigens in murine Leishmania major infection.

Authors:  Mark T M Roberts; Carmel B Stober; Andrew N McKenzie; Jenefer M Blackwell
Journal:  Infect Immun       Date:  2005-11       Impact factor: 3.441

5.  Contrasting human cytokine responses to promastigote whole-cell extract and the Leishmania analogue receptor for activated C kinase antigen of L. amazonensis in natural infection versus immunization.

Authors:  R B G Azeredo-Coutinho; D C S Matos; G G R Armôa; R M Maia; A Schubach; W Mayrink; S C F Mendonça
Journal:  Clin Exp Immunol       Date:  2008-07-08       Impact factor: 4.330

6.  Leishmania major infection in susceptible and resistant mice elicit a differential humoral response against a total soluble fraction and defined recombinant antigens of the parasite.

Authors:  Virginia Iniesta; Inés Corraliza; Jesualdo Carcelén; Luis Gómez Gordo; Javier Fernández-Cotrina; Juan Carlos Parejo; Javier Carrión; Manuel Soto; Carlos Alonso; Carlos Gómez Nieto
Journal:  Parasitol Res       Date:  2008-01-10       Impact factor: 2.289

7.  Head-to-head comparison of three vaccination strategies based on DNA and raw insect-derived recombinant proteins against Leishmania.

Authors:  Felicitat Todolí; Alhelí Rodríguez-Cortés; María Del Carmen Núñez; Márcia D Laurenti; Silvia Gómez-Sebastián; Fernando Rodríguez; Eva Pérez-Martín; José M Escribano; Jordi Alberola
Journal:  PLoS One       Date:  2012-12-07       Impact factor: 3.240

8.  Towards development of novel immunization strategies against leishmaniasis using PLGA nanoparticles loaded with kinetoplastid membrane protein-11.

Authors:  Diego M Santos; Marcia W Carneiro; Tatiana R de Moura; Kiyoshi Fukutani; Jorge Clarencio; Manuel Soto; Socorro Espuelas; Claudia Brodskyn; Aldina Barral; Manoel Barral-Netto; Camila I de Oliveira
Journal:  Int J Nanomedicine       Date:  2012-04-24

9.  Vaccination with L. infantum chagasi nucleosomal histones confers protection against new world cutaneous leishmaniasis caused by Leishmania braziliensis.

Authors:  Marcia W Carneiro; Diego M Santos; Kiyoshi F Fukutani; Jorge Clarencio; Jose Carlos Miranda; Claudia Brodskyn; Aldina Barral; Manoel Barral-Netto; Manuel Soto; Camila I de Oliveira
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

10.  Towards a more precise serological diagnosis of human tegumentary leishmaniasis using Leishmania recombinant proteins.

Authors:  Ana Paula Souza; Manuel Soto; Jackson M L Costa; Viviane S Boaventura; Camila I de Oliveira; Juqueline R Cristal; Manoel Barral-Netto; Aldina Barral
Journal:  PLoS One       Date:  2013-06-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.